• Mashup Score: 2

    In a Healio exclusive video, Tina Aswani Omprakash, a presenter at the Crohn’s and Colitis Congress, shares her experience with cultural competency as it relates to mental health and surgery for inflammatory bowel disease. “Surgery isn’t a last resort,” Omprakash, a patient advocate for Crohn’s disease and founder of the blog “Own your Crohn’s,”

    Tweet Tweets with this article
    • Watch our video with @ownyourcrohns discussing her presentation from ##CCCongress22 on cultural competency in IBD surgery VIDEO: Cultural barriers, mental health can be ‘back breaking’ for #IBD patients https://t.co/uLjw7zxFua

  • Mashup Score: 11

    Intestinal ultrasound is an accurate, noninvasive tool in the detection of postoperative Crohn’s disease recurrence, according to research presented at the Crohn’s and Colitis Congress. “Surgery for Crohn’s disease, unfortunately, is still common with a 10-year cumulative risk of 26%. We also know that endoscopic recurrence after resection is very common and patients who

    Tweet Tweets with this article
    • News from #CCCongress22: Intestinal #ultrasound effective in detecting postoperative #Crohns recurrence @AmerGastroAssn @DrMikeDolinger #GITwitter https://t.co/jYrN2cBV95

  • Mashup Score: 0

    Despite the considerable progress made in the care of inflammatory bowel disease, current therapies are “still plateauing” in terms of response and remission, according to the keynote speaker at the Crohn’s and Colitis Congress. However, combining therapies with “complementary mechanisms of action” may offer one strategy to help overcome this therapeutic plateau.

    Tweet Tweets with this article
    • #ICYMI from #CCCongress22: “In clinical practice, we are plateauing on blocking the progression of disease, especially blocking the progression to surgery,” @JeanFredericCo1 #GITwitter #IBD @AmerGastroAssn https://t.co/546YFhxNkq

  • Mashup Score: 0

    A quality improvement intervention increased vaccination adherence among patients with inflammatory bowel disease on immunosuppressive therapy, according to research presented at the Crohn’s and Colitis Congress. “Immunosuppressive therapy has really altered the course of inflammatory bowel disease in terms of prognosis and treatment,” Tony M. Cheng, MD, of the department of

    Tweet Tweets with this article
    • #ICYMI from #CCCongress22: "We want to share this intervention, because it really is a simple practice that can be adopted by other providers who treat patients with #immunosuppressive agents and can increase #vaccination rates," Tony Cheng, MD, @uthsc https://t.co/9OHOWnWuYi

  • Mashup Score: 0

    Therapeutic “de-escalation” relies on analysis of disease-related factors and careful monitoring of pediatric patients with inflammatory bowel disease, according to a presentation at the Crohn’s and Colitis Congress. “The question of therapeutic de-escalation in pediatric IBD arises so often in clinical care with the common misconception that feeling better equates to

    Tweet Tweets with this article
    • #ICYMI: “What we have today in 2022 are highly effective therapies, but we do not yet have cure. Highly effective therapy means as long as you stay on this, you're going to feel normal and you're going to be normal," Joel Rosh, MD #CCCongress22 https://t.co/CGFlz6k8dx

  • Mashup Score: 2

    Although the rate of surgery for inflammatory bowel disease has declined significantly in the era of biologic therapy, “it is still occurring,” according to a presenter at the Crohn’s and Colitis Congress. “If you think in terms of risk, about what the most disabling situation is when it comes to ulcerative colitis, it’s probably surgery, and most patients would like

    Tweet Tweets with this article
    • “If you think in terms of risk, about what the most disabling situation is when it comes to #ulcerativecolitis, it’s probably surgery, and most patients would like to avoid this at any cost,” @AngelinaIBDNP #CCCongress22 #GITwitter #IBD @AmerGastroAssn https://t.co/FnxlAV4Vb1

  • Mashup Score: 0

    A presenter at the Crohn’s and Colitis Congress discussed the latest research on COVID-19 in patients with inflammatory bowel disease. “[The COVID-19] vaccine is looking to be relatively safe for our patients in terms of their IBD disease,” Serre-Yu Wong, MD, PhD, an instructor in gastroenterology at Icahn School of Medicine at Mount Sinai, said during the presentation.

    Tweet Tweets with this article
    • COVID-19: Vaccines safe in IBD, more research needed on additional doses https://t.co/zeVwZc9blk #CCCongress22 #COVID19

  • Mashup Score: 3

    A quality improvement intervention increased vaccination adherence among patients with inflammatory bowel disease on immunosuppressive therapy, according to research presented at the Crohn’s and Colitis Congress. “Immunosuppressive therapy has really altered the course of inflammatory bowel disease in terms of prognosis and treatment,” Tony M. Cheng, MD, of the department of

    Tweet Tweets with this article
    • News from #CCCongress22: Reminder alerts improve #vaccination adherence among #IBD patients #GITwitter #COVID19 @uthsc @AmerGastroAssn https://t.co/9OHOWnWuYi